肾透明细胞癌代谢重编程及其临床意义
Metabolic Reprogramming of Clear Cell Renal Cell Carcinoma and Its Clinical Significance
DOI: 10.12677/acm.2024.1451486, PDF,   
作者: 周文昊, 岳根全*：内蒙古医科大学附属医院泌尿外科，内蒙古 呼和浩特
关键词: 肾透明细胞癌；代谢重编程；糖酵解；脂肪酸代谢；Clear Cell Renal Cell Carcinoma； Metabolic Reprogramming； Glycolysis； Fatty Acid Metabolism
摘要: 许多癌症的研究发现了控制肿瘤能量学和生物合成存在多种代谢途径。透明细胞肾细胞癌(ccRCC)是其中较为有代表性的肿瘤之一。透明细胞肾细胞癌(ccRCC)是一种代谢性疾病，其发病与代谢重编程相关。肾透明细胞癌代谢重编程的特点是参与代谢途径的靶基因发生突变，涵盖了不同的过程，如有氧糖酵解、脂肪酸代谢以及色氨酸、谷氨酰胺和精氨酸的利用。在多组学方法的时代，发现用于早期诊断的生物标志物变得越来越重要，而这些变化为新的治疗策略，生物标志物和成像方式提供了机会。特别是当肿瘤转移时，目前长期治疗选择有限，代谢重编程可以助于识别用于治疗ccRCC的新型药物。本文就当前肾透明细胞癌相关的代谢途径及代谢重编程展开论述，探究可能存在的以代谢改变为新的治疗干预或监测肿瘤生长和预后的生物标志物。
Abstract: Many cancer studies have identified multiple metabolic pathways that control tumor energetics and biosynthesis. Clear cell renal cell carcinoma (ccRCC) is one of the more representative tumors. Clear cell renal cell carcinoma (ccRCC) is a metabolic disease that is associated with metabolic reprogramming. Clear cell carcinoma metabolic reprogramming is characterized by mutations in target genes involved in metabolic pathways, covering different processes such as aerobic glycolysis, fatty acid metabolism, and utilization of tryptophan, glutamine, and arginine. In the era of multi-omics approaches, the discovery of biomarkers for early diagnosis is becoming increasingly important, and these changes provide opportunities for new therapeutic strategies, biomarkers, and imaging modalities. Especially when tumors metastasize, long-term treatment options are currently limited, and metabolic reprogramming can help identify novel drugs for the treatment of ccRCC. This article discusses the current metabolic pathways and metabolic reprogramming related to clear cell renal cell carcinoma, and explores the possible biomarkers that can be used as metabolic alterations for new therapeutic interventions or monitoring tumor growth and prognosis.
文章引用：周文昊, 岳根全. 肾透明细胞癌代谢重编程及其临床意义[J]. 临床医学进展, 2024, 14(5): 745-752. https://doi.org/10.12677/acm.2024.1451486

参考文献

[1] Levine, A.J. and Puzio-Kuter, A.M. (2010) The Control of the Metabolic Switch in Cancers by Oncogenes and Tumor Suppressor Genes. Science, 330, 1340-1344. [Google Scholar] [CrossRef] [PubMed]
[2] Deberardinis, R.J. and Chandel, N.S. (2016) Fundamentals of Cancer Metabolism. Science Advances, 2, e1600200. [Google Scholar] [CrossRef] [PubMed]
[3] Wettersten, H.I. (2020) Reprogramming of Metabolism in Kidney Cancer. Seminars in Nephrology, 40, 2-13. [Google Scholar] [CrossRef] [PubMed]
[4] Pavlova, N.N. and Thompson, C.B. (2016) The Emerging Hallmarks of Cancer Metabolism. Cell Metabolism, 23, 27-47. [Google Scholar] [CrossRef] [PubMed]
[5] Petrella, B.L. and Brinckerhoff, C.E. (2009) PTEN Suppression of YY1 Induces HIF-2 Activity in Von Hippel Lindau Null Renal Cell Carcinoma. Cancer Biology & Therapy, 8, 1389-1401. [Google Scholar] [CrossRef] [PubMed]
[6] Chakraborty, S., Balan, M., Sabarwal, A., et al. (2021) Metabolic Reprogramming in Renal Cancer: Events of a Metabolic Disease. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 1876, Article 188559. [Google Scholar] [CrossRef] [PubMed]
[7] Metallo, C.M., Gameiro, P.A., Bell, E.L., et al. (2012) Reductive Glutamine Metabolism by IDH1 Mediates Lipogenesis under Hypoxia. Nature, 481, 380-384. [Google Scholar] [CrossRef] [PubMed]
[8] Mullen, A.R. (2012) Reductive Carboxylation Supports Growth in Tumour Cells with Defective Mitochondria. Nature, 481, 385-388. [Google Scholar] [CrossRef] [PubMed]
[9] Ozcan, A., Shen, S.S., Zhai, Q.J., et al. (2007) Expression of GLUT1 in Primary Renal Tumors: Morphologic and Biologic Implications. American Journal of Clinical Pathology, 128, 245-254. [Google Scholar] [CrossRef] 
[10] Courtney, K.D., Bezwada, D., Mashimo, T., et al. (2018) Isotope Tracing of Human Clear Cell Renal Cell Carcinomas Demonstrates Suppressed Glucose Oxidation in Vivo. Cell Metabolism, 28, 793-800. [Google Scholar] [CrossRef] [PubMed]
[11] Singer, K., Kastenberger, M., Gottfried, E., et al. (2011) Warburg Phenotype in Renal Cell Carcinoma: High Expression of Glucose-Transporter 1 (GLUT-1) Correlates with Low CD8 T-Cell Infiltration in the Tumor. International Journal of Cancer, 128, 2085-2095. [Google Scholar] [CrossRef] [PubMed]
[12] Fischer, K., Hoffmann, P., Voelkl, S., et al. (2007) Inhibitory Effect of Tumor Cell-Derived Lactic Acid on Human T Cells. Blood, 109, 3812-3819. [Google Scholar] [CrossRef] [PubMed]
[13] Chan, D.A., Sutphin, P.D., Nguyen, P., et al. (2011) Targeting GLUT1 and the Warburg Effect in Renal Cell Carcinoma by Chemical Synthetic Lethality. Science Translational Medicine, 3, 94ra70. [Google Scholar] [CrossRef] [PubMed]
[14] Hakimi, A.A., Reznik, E., Lee, C.-H., et al. (2016) An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma. Cancer Cell, 29,104-116. [Google Scholar] [CrossRef] [PubMed]
[15] Mandriota, S.J. (2002) HIF Activation Identifies Early Lesions in VHL Kidneys: Evidence for Site-Specific Tumor Suppressor Function in the Nephron. Cancer Cell, 1, 459-468. [Google Scholar] [CrossRef] 
[16] Semenza, G.L. (2009) Regulation of Cancer Cell Metabolism by Hypoxia-Inducible Factor 1. Seminars in Cancer Biology, 19, 12-16. [Google Scholar] [CrossRef] [PubMed]
[17] Semenza, G.L. (2010) HIF-1: Upstream and Downstream of Cancer Metabolism. Current Opinion in Genetics & Development, 20, 51-56. [Google Scholar] [CrossRef] [PubMed]
[18] Kim, J.W., Tchernyshyov, I., Semenza, G.L., et al. (2006) HIF-1-Mediated Expression of Pyruvate Dehydrogenase Kinase: A Metabolic Switch Required for Cellular Adaptation to Hypoxia. Cell Metabolism, 3, 177-185. [Google Scholar] [CrossRef] [PubMed]
[19] Tan, Z., Luo, X., Xiao, L., et al. (2016) The Role of PGC1alpha in Cancer Metabolism and Its Therapeutic Implications. Molecular Cancer Therapeutics, 15, 774-782. [Google Scholar] [CrossRef] 
[20] Wettersten, H.I., Hakimi, A.A., Morin, D., Bianchi, C., Johnstone, M.E., Donohoe, D.R., Trott, J.F., Aboud, O.A., Stirdivant, S., Neri, B., Wolfert, R., Stewart, B., Perego, R., Hsieh, J.J. and Weiss, R.H. (2015) Grade-Dependent Metabolic Reprogramming in Kidney Cancer Revealed by Combined Proteomics and Metabolomics Analysis. Cancer Research, 75, 2541-2552. [Google Scholar] [CrossRef] 
[21] Perroud, B., Ishimaru, T., Borowsky, A.D. and Weiss, R.H. (2008) Grade-Dependent Proteomics Characterization of Kidney Cancer. Molecular & Cellular Proteomics, 8, 971-985. [Google Scholar] [CrossRef] 
[22] Yang, Y., Valera, V., Sourbier, C., et al. (2012) A Novel Fumarate Hydratase-Deficient HLRCC Kidney Cancer Cell Line, UOK268: A Model of the Warburg Effect in Cancer. Cancer Genetics, 205, 377-390. [Google Scholar] [CrossRef] [PubMed]
[23] Rohrig, F. and Schulze, A. (2016) The Multifaceted Roles of Fatty Acid Synthesis in Cancer. Nature Reviews Cancer, 16, 732-749. [Google Scholar] [CrossRef] [PubMed]
[24] Pandey, P.R., Liu, W., Xing, F., et al. (2012) Anti-Cancer Drugs Targeting Fatty Acid Synthase (FAS). Recent Patents on Anti-Cancer Drug Discovery, 7, 185-197. [Google Scholar] [CrossRef] [PubMed]
[25] Gebhard, R.L., Clayman, R.V., Prigge, W.F., et al. (1987) Abnormal Cholesterol Metabolism in Renal Clear Cell Carcinoma. Journal of Lipid Research, 28, 1177-1184. [Google Scholar] [CrossRef] 
[26] Qiu, B., Ackerman, D., Sanchez, D.J., Simon, M.C., et al. (2015) HIF2α-Dependent Lipid Storage Promotes Endoplasmic Reticulum Homeostasis in Clear-Cell Renal Cell Carcinoma. Cancer Discovery, 5, 652-667. [Google Scholar] [CrossRef] 
[27] Horiguchi, A., Asano, T., Asano, T., Sumitomo, M., Hayakawa, M., et al. (2008) Fatty Acid Synthase over Expression Is an Indicator of Tumor Aggressiveness and Poor Prognosis in Renal Cell Carcinoma. The Journal of Urology, 180, 1137-1140. [Google Scholar] [CrossRef] [PubMed]
[28] Von Roemeling, C.A., Marlow, L.A., Wei, J.J., Copland, J.A., et al. (2013) Stearoyl-CoA Desaturase 1 Is a Novel Molecular Therapeutic Target for Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 19, 2368-2380. [Google Scholar] [CrossRef] 
[29] Mungan, M.U., Gurel, D., Canda, A.E., et al. (2006) Expression of COX-2 in Normal and Pyelonephritic Kidney, Renal Intraepithelial Neoplasia, and Renal Cell Carcinoma. European Urology, 50, 92-97. [Google Scholar] [CrossRef] [PubMed]
[30] Tabriz, H.M., Mirzaalizadeh, M., Gooran, S., et al. (2016) COX-2 Expression in Renal Cell Carcinoma and Correlations with Tumor Grade, Stage and Patient Prognosis. Asian Pacific Organization for Cancer Prevention, 17, 535-538. [Google Scholar] [CrossRef] 
[31] Wettersten, H.I., Aboud, O.A., Lara, P.N., et al. (2017) Metabolic Reprogramming in Clear Cell Renal Cell Carcinoma. Nature Reviews Nephrology, 13, 410-419. [Google Scholar] [CrossRef] [PubMed]
[32] Li, H., Bullock, K., Gurjao, C., et al. (2019) Metabolomic Adaptations and Correlates of Survival to Immune Checkpoint Blockade. Nature Communications, 10, Article No. 4346. [Google Scholar] [CrossRef] [PubMed]
[33] Hassanein, M., Hoeksema, M.D., Shiota, M., et al. (2013) SLC1A5 Mediates Glutamine Transport Required for Lung Cancer Cell Growth and Survival. Clinical Cancer Research, 19, 560-570. [Google Scholar] [CrossRef] 
[34] Matés, J.M., Segura, J.A., Martín-Rufián, M., et al. (2013) Glutaminase Isoenzymes as Key Regulators in Metabolic and Oxidative Stress against Cancer. Current Molecular Medicine, 13, 514-534. [Google Scholar] [CrossRef] [PubMed]
[35] Mannava, S., Grachtchouk, V., Wheeler, L.J., Im, M., Zhuang, D., et al. (2008) Direct Role of Nucleotide Metabolism in C-MYC-Dependent Proliferation of Melanoma Cells. Cell Cycle, 7, 2392-2400. [Google Scholar] [CrossRef] [PubMed]
[36] Shroff, E.H., Eberlin, L.S., Dang, V.M., et al. (2015) MYC Oncogene Overexpression Drives Renal Cell Carcinoma in a Mouse Model through Glutamine Metabolism. Proceedings of the National Academy of Sciences, 112, 6539-6544. [Google Scholar] [CrossRef] [PubMed]
[37] Bowles, T.L., Kim, R., Galante, J., et al. (2008) Pancreatic Cancer Cell Lines Deficient in Argininosuccinate Synthetase Are Sensitive to Arginine Deprivation by Arginine Deiminase. International Journal of Cancer, 123, 1950-1955. [Google Scholar] [CrossRef] [PubMed]
[38] Ensor, C.M., Holtsberg, F.W., Bomalaski, J.S., et al. (2002) Pegylated Arginine Deiminase (ADI-SS PEG20,000 mw) Inhibits Human Melanomas and Hepatocellular Carcinomas in vitro and in vivo. Cancer Research, 62, 5443-5450.
[39] Yoon, C.-Y., Shim, Y.-J., Kim, E.-H., et al. (2007) Renal Cell Carcinoma Does Not Express Argininosuccinate Synthetase and Is Highly Sensitive to Arginine Deprivation via Arginine Deiminase. International Journal of Cancer, 120, 897-905. [Google Scholar] [CrossRef] [PubMed]
[40] Rabinovich, S., Adler, L., Yizhak, K., et al. (2015) Diversion of Aspartate in ASS1-Deficient Tumours Fosters de novo Pyrimidine Synthesis. Nature, 527, 379-383. [Google Scholar] [CrossRef] [PubMed]
[41] Yoon, J.K., Frankel, A.E., Feun, L.G., et al. (2013) Arginine Deprivation Therapy for Malignant Melanoma. Clinical Pharmacology: Advances and Applications, 5, 11-19. [Google Scholar] [CrossRef] 
[42] Jiang, P., Du, W. and Wu, M. (2014) Regulation of the Pentose Phosphate Pathway in Cancer. Protein & Cell, 5, 592-602. [Google Scholar] [CrossRef] [PubMed]
[43] Aykin-Burns, N., Ahmad, I.M., Zhu, Y., et al. (2009) Increased Levels of Superoxide and H2O2 Mediate the Differential Susceptibility of Cancer Cells versus Normal Cells to Glucose Deprivation. Biochemical Journal, 418, 29-37. [Google Scholar] [CrossRef] 
[44] Nogueira, V. and Hay, N. (2013) Molecular Pathways: Reactive Oxygen Species Homeostasis in Cancer Cells and Implications for Cancer Therapy. Clinical Cancer Research, 19, 4309-4314. [Google Scholar] [CrossRef] 
[45] Langbein, S., Frederiks, W.M., Hausen, A.Z., et al. (2008) Metastasis Is Promoted by a Bioenergetic Switch: New Targets for Progressive Renal Cell Cancer. International Journal of Cancer, 122, 2422-2428. [Google Scholar] [CrossRef] [PubMed]
[46] Lucarelli, G., Galleggiante, V., Rutigliano, M., et al. (2015) Metabolomic Profile of Glycolysis and the Pentose Phosphate Pathway Identifies the Central Role of Glucose-6-Phosphate Dehydrogenase in Clear Cell-Renal Cell Carcinoma. Oncotarget, 6, 13371-13386. [Google Scholar] [CrossRef] [PubMed]
[47] Schmidinger, M. (2013) Understanding and Managing Toxicities of Vascular Endothelial Growth Factor (VEGF) Inhibitors. European Journal of Cancer Supplements, 11, 172-191. [Google Scholar] [CrossRef] [PubMed]
[48] Chen, W., Hill, H., Christie, A., et al. (2016) Targeting Renal Cell Carcinoma with a HIF-2 Antagonist. Nature, 539, 112-117. [Google Scholar] [CrossRef] [PubMed]
[49] Gross, M.I., Demo, S.D., et al. (2014) Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 13, 890-901. [Google Scholar] [CrossRef] 
[50] Trott, J.F., Kim, J., et al. (2016) Inhibiting Tryptophan Metabolism Enhances Interferon Therapy in Kidney Cancer. Oncotarget, 7, 66540-66557. [Google Scholar] [CrossRef] [PubMed]
[51] Benita, Y., Kikuchi, H., Smith, A.D., et al. (2009) An Integrative Genomics Approach Identifies Hypoxia Inducible Factor-1 (HIF-1)-Target Genes that form the Core Response to Hypoxia. Nucleic Acids Research, 37, 4587-4602. [Google Scholar] [CrossRef] [PubMed]

为你推荐